Cytosorbents (CTSO) PT Set at $12.00 by Maxim Group
Other equities analysts have also issued reports about the company. HC Wainwright reissued a buy rating and issued a $13.00 price target on shares of Cytosorbents in a research note on Tuesday, November 21st. B. Riley reissued a buy rating and issued a $11.25 price target on shares of Cytosorbents in a research note on Friday, November 10th. Finally, ValuEngine raised Cytosorbents from a sell rating to a hold rating in a research note on Wednesday, September 6th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $10.40.
Cytosorbents (CTSO) opened at $6.70 on Thursday. Cytosorbents has a 12 month low of $3.30 and a 12 month high of $7.05. The company has a quick ratio of 3.17, a current ratio of 3.36 and a debt-to-equity ratio of 0.73. The stock has a market capitalization of $196.63, a P/E ratio of -17.63 and a beta of -0.53.
In other news, COO Vincent Capponi sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, November 27th. The stock was sold at an average price of $7.00, for a total transaction of $28,000.00. Following the completion of the sale, the chief operating officer now owns 271,062 shares in the company, valued at $1,897,434. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 5.60% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wealthcare Advisory Partners LLC bought a new stake in Cytosorbents during the third quarter worth $365,000. PNC Financial Services Group Inc. grew its holdings in Cytosorbents by 145.2% during the second quarter. PNC Financial Services Group Inc. now owns 38,000 shares of the medical research company’s stock worth $163,000 after buying an additional 22,500 shares in the last quarter. Finally, Fortaleza Asset Management Inc. grew its holdings in Cytosorbents by 81.6% during the third quarter. Fortaleza Asset Management Inc. now owns 23,375 shares of the medical research company’s stock worth $145,000 after buying an additional 10,500 shares in the last quarter. Hedge funds and other institutional investors own 8.65% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was first published by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.watchlistnews.com/cytosorbents-ctso-pt-set-at-12-00-by-maxim-group/1781995.html.
Cytosorbents Company Profile
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with Analyst Ratings Network's FREE daily email newsletter.